Core Insights - Boxer Capital Management, LLC disclosed the purchase of 386,000 shares of Kodiak Sciences, valued at approximately $7.90 million based on the average price from the previous quarter [2][3] - The value of Kodiak Sciences in Boxer Capital's portfolio increased by $19.49 million since the last filing, reflecting both new purchases and share price appreciation [2] - Kodiak Sciences shares have seen a significant price increase of 340% over the past year, outperforming the S&P 500 by 318.88 percentage points [3] Company Overview - Kodiak Sciences is a clinical-stage biotechnology company focused on developing therapies for retinal diseases, utilizing an antibody biopolymer conjugate platform [6] - The company's lead candidate, KSI-301, is in late-stage trials targeting wet age-related macular degeneration and other retinal conditions [8] - As of February 17, 2026, Kodiak Sciences has a market capitalization of $1.20 billion and a net income of -$217.34 million [4] Investment Implications - Kodiak Sciences now represents 6.95% of Boxer Capital's reportable assets under management (AUM), making it a significant holding for the firm [3] - The stock's performance has been exceptional, with a 564% increase over the past year, indicating strong investor interest and confidence in the company's future prospects [10]